ArticlePragmatic and observational research2025
Real-World Treatment Patterns and Overall Survival (OS) of Patients with Metastatic Castration-Resistant Prostate Cancer in Italy.
Article in Pragmatic and observational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This real-world analysis described the characteristics and therapeutic management of patients with metastatic castration-resistant prostate cancer (mCRPC) in Italy before and after 2015, when androgen receptor signalling inhibitors (ARPI) entered clinical practice. Patients and Methods: An observational retrospective analysis was conducted using administrative healthcare databases from a pool of Italian Local Health Units, covering ~6.2 million residents. Adult men with ≥1 prescription of androgen deprivation therapy (ADT) from January 2011 to June 2022 were identified. mCRPC was proxied by treatment patterns-addition of docetaxel/cabazitaxel or ARPI to ADT-and confirmed by hospital discharge for metastasis. Patients were stratified according to their inclusion (date of the last inclusion criterion met): pre-2015 (2011-2014) and post-2015 (2015-2020). Results: Among 1890 mCRPC patients identified, 551 (29%) received ≥2 treatment lines. Chemotherapy (CHT) was the predominant first-line (1L) therapy in both cohorts [97.2% vs 82.9%], followed by ARPI [2.8% vs 17.1%]. In a 2020 sensitivity analysis (n=406), 1L therapy was ARPI in 76% and CHT in 24%. Among pre- and post-2015 patients, 29.4% and 31.6% received second-line (2L) therapy, mostly ARPI. Median OS from ADT initiation was 46.4 months (pre-2015) and 53.9 months (post-2015). In post-2015 patients, median OS from mCRPC index-date-reflecting the proxy-based diagnosis-was 14.2 months. Conclusion: In Italian clinical practice, CHT remains the most common 1L therapy though ARPI use has increased since 2015. While OS from ADT initiation has improved, survival from mCRPC diagnosis-based on proxies in administrative data-remains poor, underscoring an unmet clinical need. Differences in OS estimates depending on the starting point (ADT initiation vs mCRPC diagnosis) should be considered when interpreting results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.